Dry Eyes

Keratoconjunctivitis sicca, commonly known as dry eye, is a chronic ophthalmic condition in which the lacrimal glands fail to produce an adequate quantity of the aqueous component of the tear film. The tear film is a complex three-layered structure consisting of a lipid outer layer, an aqueous middle layer, and a mucin inner layer, each playing a critical role in maintaining corneal health, optical clarity, and immune defense. When the aqueous portion is deficient, the cornea and conjunctiva become chronically inflamed and are left vulnerable to infection, ulceration, and scarring.

Dry eye is one of the most frequently diagnosed ocular conditions in veterinary ophthalmology. It affects dogs of all ages, though it is most commonly identified in middle-aged to older animals. The condition can be unilateral, affecting only one eye, but bilateral involvement is far more typical. Without treatment, KCS progresses steadily, causing significant discomfort and eventually leading to visual impairment or blindness.

The tear film serves several essential functions beyond simple lubrication. It delivers oxygen and nutrients to the avascular cornea, removes metabolic waste products, provides antimicrobial defense through immunoglobulins and lysozymes, and creates a smooth refractive surface for clear vision. When tear production drops below normal thresholds, all of these protective mechanisms are compromised simultaneously, creating a cascade of pathological changes on the ocular surface.

Dogs with dry eye often present with a characteristic thick, mucopurulent discharge that owners may initially mistake for a simple eye infection. Unlike bacterial conjunctivitis, however, KCS does not resolve with antibiotic therapy alone and requires specific treatment aimed at restoring tear production or supplementing the tear film to prevent progressive corneal damage.

The most common cause of dry eye in dogs is immune-mediated destruction of the lacrimal gland tissue. In this form, the body's own immune system targets and progressively destroys the cells responsible for producing the aqueous component of tears. This autoimmune process accounts for the majority of KCS cases and explains why the condition is often bilateral and tends to be chronic and progressive without immunosuppressive therapy.

Certain medications are well-documented causes of KCS. Sulfonamide antibiotics, particularly sulfasalazine and trimethoprim-sulfa combinations, can cause either temporary or permanent lacrimal gland damage. Atropine and other anticholinergic agents reduce tear secretion through their parasympatholytic effects. Nonsteroidal anti-inflammatory drugs and certain anesthetic agents may also temporarily diminish tear output. Drug-induced KCS may be reversible if the offending medication is discontinued promptly, but prolonged exposure can result in permanent gland damage.

Congenital and developmental causes include lacrimal gland hypoplasia or aplasia, where the glands fail to develop properly. Neurogenic KCS occurs when damage to the parasympathetic nerve supply to the lacrimal glands disrupts the neural signals necessary for tear secretion. This form is often unilateral and may be accompanied by ipsilateral dryness of the nostril on the affected side. Trauma, surgery near the eye or ear, and middle ear disease can all damage the relevant nerve pathways.

Endocrine disorders, particularly hypothyroidism and diabetes mellitus, have been associated with an increased incidence of KCS. Canine distemper virus can cause permanent lacrimal gland destruction during acute infection. Radiation therapy involving the head region and surgical removal of the third eyelid gland (cherry eye surgery performed incorrectly) are additional recognized causes. The third eyelid gland contributes approximately 30 to 50 percent of total tear production, making its preservation critically important during any corrective surgical procedure.

Breed predisposition plays a significant role, with brachycephalic breeds and certain spaniel and terrier breeds showing markedly higher incidence rates. This breed clustering strongly supports a genetic component to immune-mediated lacrimal gland destruction. Environmental factors such as dry climates, air conditioning, and exposure to wind or dust may exacerbate symptoms in predisposed animals but are not considered primary causes of the condition.

The hallmark clinical sign of KCS is a thick, ropy, yellowish-green mucopurulent discharge that accumulates around the eyes and along the eyelid margins. This discharge results from the overproduction of mucus by conjunctival goblet cells attempting to compensate for the absent aqueous tear component. Owners frequently report needing to clean their dog's eyes multiple times daily, and the discharge often returns within hours of being removed.

Conjunctival hyperemia, or redness of the tissue lining the eyelids and covering the white of the eye, is a consistent finding. The conjunctiva becomes chronically inflamed and may appear thickened or edematous. Dogs often exhibit blepharospasm, which is squinting or involuntary closure of the eyelids due to ocular discomfort. Pawing at the eyes, rubbing the face on furniture or carpeting, and increased blinking frequency are behavioral indicators of the irritation caused by inadequate tear coverage.

As the condition progresses, the cornea undergoes a series of pathological changes. Corneal vascularization occurs as blood vessels grow inward from the limbus in response to chronic inflammation and hypoxia. Pigmentation of the corneal surface, known as corneal melanosis, develops as melanocytes migrate across the cornea in a protective response to chronic irritation and ultraviolet exposure. This pigmentation can become dense enough to significantly obstruct vision, appearing as a dark brown or black discoloration spreading across the corneal surface.

Corneal ulceration is a serious complication of untreated or poorly controlled KCS. Without the protective tear film, the corneal epithelium becomes fragile and susceptible to mechanical trauma from normal blinking and environmental debris. These ulcers may become secondarily infected with bacteria, potentially progressing to deep stromal ulcers or corneal perforation if not treated aggressively. Signs of corneal ulceration include sudden increase in pain, excessive tearing from reflex mechanisms, cloudiness of the cornea, and visible defects on the corneal surface.

The overall appearance of the eye in chronic KCS is dull and lusterless, lacking the normal healthy sheen provided by an intact tear film. In advanced cases, the cornea may become completely opacified by a combination of vascularization, pigmentation, fibrosis, and lipid deposits, rendering the dog functionally blind in the affected eye or eyes.

The Schirmer tear test (STT) is the gold standard diagnostic procedure for KCS and is performed routinely in veterinary ophthalmology. A standardized strip of absorbent filter paper is placed in the lower conjunctival fornix for exactly 60 seconds, and the length of wetting is measured in millimeters. Normal canine tear production is typically 15 to 25 millimeters per minute. Values between 10 and 15 millimeters per minute are considered borderline or early KCS, while readings below 10 millimeters per minute confirm the diagnosis. Values below 5 millimeters per minute indicate severe disease requiring aggressive therapeutic intervention.

Fluorescein staining is an essential complementary test used to evaluate corneal integrity. A drop of fluorescein dye is applied to the ocular surface and the cornea is examined under cobalt blue light. Areas of epithelial loss or ulceration retain the dye and fluoresce bright green, allowing the clinician to identify corneal damage that may not be visible on routine examination. Rose bengal staining is another diagnostic dye that highlights devitalized or poorly protected epithelial cells, providing additional information about the health of the ocular surface.

A thorough ophthalmic examination using a slit lamp biomicroscope allows detailed evaluation of the cornea, anterior chamber, iris, and lens. This examination reveals the extent of corneal pathology including vascularization depth, pigmentation distribution, stromal edema, and the presence of any anterior chamber inflammation. Intraocular pressure measurement using tonometry is performed to rule out concurrent glaucoma, which can occasionally coexist with KCS.

Cytological examination of conjunctival swabs or scrapings may be performed in cases where infection is suspected or to characterize the inflammatory cell population. Bacterial culture and sensitivity testing are indicated when corneal ulceration is present or when the discharge pattern suggests secondary bacterial infection. These tests guide appropriate antibiotic selection and help distinguish between primary infection and secondary contamination of an already compromised ocular surface.

Additional diagnostic workup may include systemic blood tests to evaluate thyroid function, blood glucose levels, and immune markers, particularly when KCS is suspected to be part of a broader systemic condition. Breed history, medication history, and any previous ocular surgeries are critical components of the diagnostic evaluation, as they may identify the underlying etiology and influence treatment planning.

The cornerstone of KCS treatment is topical immunosuppressive therapy aimed at halting immune-mediated destruction of the lacrimal glands and stimulating residual gland tissue to produce tears. Cyclosporine A, available as a 0.2 percent ophthalmic ointment (Optimmune) or compounded at various concentrations, is the most widely used lacrimostimulant. Cyclosporine works by inhibiting T-lymphocyte activation and suppressing the local immune response within the lacrimal gland, allowing surviving glandular tissue to resume tear production. Most dogs show measurable improvement in tear production within two to six weeks of initiating therapy, though maximum effect may take eight to twelve weeks.

Tacrolimus, a more potent immunosuppressive agent, is used as a second-line treatment when cyclosporine fails to produce an adequate response. Available as a compounded ophthalmic solution or ointment at concentrations of 0.02 to 0.03 percent, tacrolimus has demonstrated effectiveness in many cyclosporine-refractory cases. The mechanism of action is similar to cyclosporine but acts on a different intracellular pathway, making it a valuable alternative for dogs that do not respond to first-line therapy.

Artificial tear supplements are used as adjunctive therapy to provide immediate symptomatic relief and protect the corneal surface while immunosuppressive medications take effect. Viscous preparations containing hyaluronic acid, carboxymethylcellulose, or polyvinyl alcohol provide longer-lasting lubrication than simple saline-based drops. These supplements must be applied frequently, often every two to four hours, to maintain adequate corneal protection. They do not address the underlying disease and should never be used as sole therapy when lacrimostimulant treatment is an option.

Topical antibiotics are prescribed when secondary bacterial infection is present or when corneal ulceration occurs. Broad-spectrum options such as neomycin-polymyxin-bacitracin combinations or fluoroquinolones like ofloxacin or ciprofloxacin are commonly used. Anti-inflammatory agents, including topical corticosteroids or nonsteroidal anti-inflammatory drugs, may be judiciously employed to reduce corneal and conjunctival inflammation, but corticosteroids must be used with extreme caution and are strictly contraindicated in the presence of corneal ulceration due to the risk of potentiating corneal melting.

In cases refractory to all medical therapy, surgical intervention with parotid duct transposition may be considered. This procedure redirects the parotid salivary duct to deliver saliva to the ocular surface as a tear substitute. While effective at providing moisture, saliva differs from tears in composition and pH, and mineral deposits on the cornea and periocular skin irritation are common long-term complications. This surgery is reserved for severe cases where medical management has completely failed and the dog faces blindness without intervention.

Consistent medication administration is the single most important factor in successful home management of KCS. Owners must commit to applying topical medications on a strict schedule, as even brief interruptions in treatment can allow the inflammatory process to reactivate and cause additional lacrimal gland damage. Setting alarms, integrating medication times into daily routines, and keeping medications in visible, accessible locations all help maintain compliance with the treatment regimen.

Gentle daily cleaning of the eyes and periocular area is essential for comfort and hygiene. Using a warm, damp, soft cloth or gauze pad, owners should carefully remove accumulated discharge from the eyelids, eyelashes, and surrounding fur. Cleaning should always be performed before applying medications to ensure proper drug contact with the ocular surface. The wiping motion should be directed away from the eye to prevent pushing debris toward the cornea. Separate cloths should be used for each eye if bilateral disease is present to avoid cross-contamination.

Environmental modifications can significantly improve comfort for dogs with KCS. Reducing exposure to wind, dust, cigarette smoke, and other airborne irritants helps minimize additional ocular surface stress. In dry climates or during winter months when indoor heating reduces humidity, using a room humidifier in areas where the dog spends the most time can help reduce tear evaporation. Avoiding direct airflow from fans, heating vents, or air conditioning onto the dog's face is also beneficial.

Regular veterinary follow-up appointments are critical for monitoring disease progression and treatment response. Schirmer tear tests should be repeated at regular intervals to assess whether tear production is improving, stable, or declining. The frequency of corneal evaluation helps detect complications such as ulceration early, when they are most treatable. Owners should be educated on signs that warrant immediate veterinary attention, including sudden increase in squinting, change in discharge color or volume, cloudiness of the eye, and any apparent visual changes.

Nutritional support may play a supplementary role in managing ocular health. Omega-3 fatty acid supplementation has shown some benefit in supporting tear film stability and reducing ocular surface inflammation in both human and veterinary studies. A balanced, high-quality diet supports overall immune function and may help modulate the autoimmune component of the disease. However, nutritional interventions should always be discussed with a veterinarian and used as complements to, never replacements for, standard medical therapy.

The prognosis for dogs with KCS depends heavily on the underlying cause, the severity at the time of diagnosis, and the consistency of long-term treatment. Dogs diagnosed early, before significant corneal damage has occurred, and treated promptly with appropriate immunosuppressive therapy generally have a favorable prognosis for maintaining comfortable, functional vision throughout their lives. The majority of dogs respond positively to cyclosporine or tacrolimus therapy, with measurable increases in tear production and visible improvement in ocular surface health.

Cases identified at more advanced stages, where corneal scarring, dense pigmentation, or chronic ulceration have already developed, carry a more guarded prognosis for visual recovery. While treatment can halt further progression and improve comfort, established corneal changes such as deep scarring and heavy pigment deposits are often permanent. Some degree of vision loss may persist even with optimal medical management, though many dogs adapt remarkably well to reduced vision.

Drug-induced KCS generally carries the best prognosis, as discontinuation of the offending medication often allows partial or complete recovery of lacrimal gland function if the exposure duration was relatively brief. Neurogenic KCS may also have a favorable prognosis depending on whether the underlying nerve injury is temporary or permanent. Congenital forms with absent or severely hypoplastic glands and advanced autoimmune cases with near-complete gland destruction present the greatest therapeutic challenges.

KCS is a lifelong condition in most cases, requiring ongoing treatment without interruption. Owners should understand that discontinuing medication, even when the eyes appear healthy, typically leads to disease relapse within weeks as the immune-mediated destruction of lacrimal tissue resumes. Treatment costs, including medications and regular veterinary examinations, should be anticipated as a long-term commitment. Many dogs with well-managed KCS enjoy a normal quality of life and lifespan with no significant impact on their daily activities.

Periodic reassessment of the treatment protocol is important, as individual responses may change over time. Some dogs require dosage adjustments, medication changes, or the addition of supplemental therapies as the disease evolves. A collaborative relationship between the owner and veterinary team, supported by regular monitoring and open communication, is essential for achieving the best possible long-term outcome.

Corneal ulceration is the most clinically significant complication of KCS and represents a true ophthalmic emergency when it occurs. The compromised corneal surface, deprived of the protective tear film, is highly susceptible to epithelial breakdown from routine mechanical forces such as blinking. Superficial ulcers may deepen rapidly in the setting of KCS, progressing to stromal ulcers, descemetoceles, or even corneal perforation. Any sign of acute pain, sudden onset of squinting, or corneal cloudiness in a dog with known KCS warrants immediate veterinary evaluation.

Secondary bacterial and fungal infections are common complications due to the loss of antimicrobial components normally present in the tear film. The stagnant mucoid discharge that accumulates in KCS provides an excellent growth medium for opportunistic organisms. Staphylococcus, Streptococcus, and Pseudomonas species are frequently cultured from infected KCS eyes. Pseudomonas infections are particularly dangerous due to their capacity to produce collagenase enzymes that rapidly dissolve corneal stroma, leading to the devastating complication known as corneal melting.

Chronic corneal changes including vascularization, pigmentation, and fibrosis can progressively impair vision even in the absence of ulceration. These changes represent the cornea's attempt to protect and repair itself in the face of ongoing inflammation and desiccation. While some degree of vascularization may regress with effective treatment, dense pigmentation and deep stromal scarring are generally irreversible. In severe cases, the entire corneal surface may become opaque, resulting in functional blindness.

KCS is occasionally associated with other immune-mediated conditions, including dry mouth (xerostomia), hypothyroidism, immune-mediated polyarthritis, and atopic dermatitis. The coexistence of multiple autoimmune conditions in a single patient is not uncommon and may reflect a broader dysregulation of immune tolerance. Dogs diagnosed with KCS should be evaluated for systemic signs of immune-mediated disease, and those with known autoimmune conditions should have routine ophthalmic screening.

Psychological and behavioral effects of chronic ocular discomfort should not be underestimated. Dogs with poorly controlled KCS may become irritable, withdrawn, or reluctant to engage in normal activities. Reduced vision can lead to anxiety, increased startle responses, and navigational difficulties, particularly in unfamiliar environments or low-light conditions. Addressing pain and discomfort through effective medical management significantly improves overall quality of life and behavioral wellbeing.

Brachycephalic breeds are among the most commonly affected by KCS, with English Bulldogs, Pugs, Shih Tzus, Lhasa Apsos, and Boston Terriers all demonstrating significantly elevated risk compared to the general canine population. The shallow orbits and prominent globe positioning characteristic of these breeds contribute to increased corneal exposure and tear film evaporation, compounding the effects of any reduction in tear production. Their facial conformation also predisposes them to incomplete blink reflexes, further reducing tear distribution across the corneal surface.

Cocker Spaniels, both American and English varieties, are among the breeds with the highest reported prevalence of KCS. Studies have documented prevalence rates several times higher than the general population in this breed. The condition tends to present at a younger age in Cocker Spaniels compared to many other breeds, and bilateral involvement is the rule rather than the exception. The strong breed predilection suggests a significant genetic component to the immune-mediated form of the disease in this breed.

West Highland White Terriers have a well-documented predisposition to KCS that frequently occurs alongside other immune-mediated conditions, including atopic dermatitis and inflammatory bowel disease. This clustering of autoimmune disorders in a single breed supports the hypothesis of shared genetic susceptibility to immune dysregulation. Yorkshire Terriers, Miniature Schnauzers, and certain other terrier breeds also show increased prevalence.

Cavalier King Charles Spaniels are predisposed to KCS and often develop the condition in conjunction with other breed-related health issues including mitral valve disease and syringomyelia. Bloodhounds, with their characteristic loose facial skin and prominent lower eyelids, are predisposed to both KCS and other ocular conditions related to their facial conformation. Samoyeds and certain other northern breeds have also been reported at increased risk.

While breed predisposition provides valuable guidance for heightened surveillance and early detection, it is important to recognize that KCS can develop in any breed, including mixed-breed dogs. Age is an additional risk factor independent of breed, with the highest incidence occurring in dogs between four and twelve years of age. Female dogs appear to be affected slightly more frequently than males, though both sexes are well represented in affected populations. Awareness of breed and demographic risk factors enables proactive screening and early intervention, which significantly improves long-term outcomes.

While true prevention of immune-mediated KCS is not currently possible, several strategies can reduce the risk of acquired forms and improve outcomes through early detection. Owners of predisposed breeds should establish a relationship with a veterinary ophthalmologist or ensure their primary care veterinarian performs routine Schirmer tear testing during annual wellness examinations. Baseline tear production values obtained when the dog is healthy provide a reference point for detecting early decline before clinical signs become apparent.

Awareness of medication-related risks is an important preventive consideration. When sulfonamide antibiotics or other drugs known to affect tear production must be used, monitoring tear production before, during, and after treatment allows early detection of drug-induced lacrimal gland damage. If a decrease in tear production is noted, prompt discontinuation of the offending drug and initiation of supportive therapy may prevent permanent gland injury. Owners should inform all treating veterinarians of their dog's KCS risk factors so that alternative medications can be selected when possible.

Preservation of the third eyelid gland during cherry eye surgery is a critical preventive measure. The prolapsed gland of the third eyelid should always be repositioned surgically rather than excised. Removal of this gland eliminates a substantial portion of the eye's tear-producing capacity and significantly increases the risk of KCS developing later in life. Owners whose dogs develop cherry eye should seek surgical correction from an experienced veterinary ophthalmologist who employs gland-sparing techniques.

Early recognition of clinical signs by owners plays a vital role in achieving the best treatment outcomes. Excessive eye discharge, redness, squinting, and a dull corneal appearance should prompt veterinary evaluation rather than home treatment with over-the-counter eye drops. Many cases of KCS are initially managed at home by well-meaning owners using artificial tears or antibiotic drops purchased without veterinary guidance, delaying definitive diagnosis and allowing progressive gland destruction to continue unchecked.

Breeder education and responsible breeding practices contribute to long-term prevention at the population level. Breeders of predisposed breeds should be aware of KCS prevalence in their lines and consider ophthalmic screening of breeding animals. While the genetics of immune-mediated KCS are complex and not amenable to simple genetic testing at this time, selecting breeding stock with documented healthy tear production and free of clinical KCS reduces the propagation of susceptibility genes within affected breeds.